Gene Therapy for Transfusion Dependent Beta-thalassemia (TIGET-BTHAL)
A Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem Cells Genetically Modified With GLOBE Lentiviral Vector Encoding for the Human Beta-globin Gene for the Treatment of Patients Affected by Transfusion Dependent Beta-thalassemia
Sponsor: Fondazione Telethon
Listed as NCT02453477, this PHASE1/PHASE2 trial focuses on Beta-Thalassemia and remains ongoing. Sponsored by Fondazione Telethon, it has been updated 9 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jul 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2018 — Jul 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Mar 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fondazione Telethon
- IRCCS San Raffaele
- Orchard Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .